Pancreatic cancer is one of the deadliest cancers, with low survival rates once the disease metastasizes. Current treatments, including chemotherapy combinations, have modest outcomes. However, recent developments in KRAS inhibitors, previously considered “undruggable,” show promise for treating pancreatic cancer. Two inhibitors have been approved for other cancers, with several others in development specifically targeting pancreatic cancer. Initial results show potential for improved outcomes, with ongoing research exploring combination therapies. While some experts remain cautious, others are optimistic about the future of treating pancreatic cancer. Mutation testing will be crucial to identify patients who may benefit from these new treatments.
Source link
KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?
